^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    p38 inhibitor

    Related drugs:
    1m
    BMP-7 Treatment Ameliorates PTEN-Akt Mediated Apoptosis and Adverse Cardiac Remodeling in Ponatinib-Induced Cardiotoxicity. (PubMed, Pharmaceuticals (Basel))
    These results suggest that BMP-7 might inhibit PON-induced cardiotoxicity. Furthermore, our findings pave the way for future translational studies with BMP-7, which can demonstrate the therapeutic potential of BMP-7 in a clinical setting.
    Journal • IO biomarker
    |
    PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
    |
    Iclusig (ponatinib)
    2ms
    A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects (clinicaltrials.gov)
    P1, N=6, Recruiting, GEn1E Lifesciences | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    Systems-level exploration of Withania somnifera-derived phytochemicals against breast cancer: A network pharmacology and molecular modeling approach. (PubMed, Comput Biol Med)
    Therefore, Viscosalactone B and Withasomniferol C are promising natural candidates for further validation as potential MAPK14 inhibitors. In comparison with synthetic drugs like ralimetinib, these plant-derived compounds may offer complementary therapeutic potential with fewer adverse or off-target effects and favorable pharmacokinetic and pharmacophoric profiles.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • MAPK14 (Mitogen-Activated Protein Kinase 14) • RELA (RELA Proto-Oncogene)
    |
    ralimetinib (LY 2228820)
    2ms
    NFATc1 activates the Ras/Raf/p38 MAPK pathway to promote the progression of lung adenocarcinoma. (PubMed, Transl Cancer Res)
    Pretreatment with the inhibitor SB202190 decreased the expression of proteins related to Ras/Raf/p38 MAPK and significantly suppressed the proliferation, migration, and invasion of A549 cells...NFATc1 is highly expressed in LUAD tissues, and its expression level is closely related to clinical characteristics. NFATc1 may promote the proliferation, migration, and LUAD cell invasion via the Ras/Raf/p38 MAPK pathway, providing a new therapeutic target for LUAD.
    Journal
    |
    NFATC1 (Nuclear Factor Of Activated T Cells 1)
    |
    SB202190
    3ms
    Osteopontin Promotes Liver Echinococcus multilocularis Growth and Invasion via p38MAPK Pathway. (PubMed, Parasite Immunol)
    The mice in the anti-p38MAPK group and the anti-p38MAPK + LV-OPN-0423 group were then given SB202190 (this is an inhibitor of p38MAPK) for 4 weeks, and the mice in each group were injected with corresponding lentivirus diluent once a week for 8 weeks...The OPN level promoted the expression of p38MAPK and p-p38MAPK. These results suggested that OPN could regulate Em's growth and metastasis through the p38MAPK signalling pathway in host hepatocytes, providing evidence that OPN and p38MAPK may be novel molecular targets for treating alveolar echinococcosis.
    Journal
    |
    SPP1 (Secreted Phosphoprotein 1)
    |
    SB202190
    3ms
    Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab (clinicaltrials.gov)
    P1/2, N=70, Active, not recruiting, Dan Zandberg | Trial completion date: Oct 2025 --> Dec 2025
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • pexmetinib (ARRY-614)
    3ms
    A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS) (clinicaltrials.gov)
    P2, N=52, Recruiting, GEn1E Lifesciences | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    4ms
    A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, EIP Pharma Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    4ms
    A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy Subjects (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, GEn1E Lifesciences
    New P1 trial
    6ms
    Promoting mitochondrial fusion is protective against cancer-induced muscle detriments in males and females. (PubMed, BMC Cancer)
    Promoting mitochondrial fusion via OPA1 induction improved cachectic outcomes in mice. Targeting OPA1providing provides a promising therapeutic approach for CC treatment.
    Journal
    |
    FOXO3 (Forkhead box O3) • CEACAM1 (CEA Cell Adhesion Molecule 1)
    7ms
    Estrogen-mediated corneal collagen degradation in keratoconus. (PubMed, iScience)
    Our model showed that both corneal epithelium and fibroblasts synthesize their own estrogen, and β-estradiol treatment via p38 MAP kinase pathway regulates MMP2-mediated collagen fiber degradation. p38 MAP kinase inhibitor SB202190 significantly reduced β-estradiol-induced MMP activity and collagen breakdown, as well as cytokine regulation suggesting a potential therapeutic approach.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • MMP2 (Matrix metallopeptidase 2) • IGFBP3 (Insulin-like growth factor binding protein 3)
    |
    SB202190
    7ms
    A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies (clinicaltrials.gov)
    P2, N=25, Recruiting, EIP Pharma Inc | Trial completion date: Jan 2026 --> Apr 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date